New Study and White Paper Confirm Findings
Download the white paper now!
With continued, accelerated rates of adult obesity and Type 2 diabetes—along with an aging population—non-alcoholic fatty liver disease (NAFLD) and mortality are expected to increase in the United States and globally. These trends prompt demand for earlier screening and strategies to curb the staggering costs associated with fatty liver disease (FLD). Fortunately, there is good news for payers, providers and patients.
A study published in the American Journal of Managed Care (AJMC), “Population-Based Return on Investment of Deploying Transient Elastography Screening and Monitoring Fatty Liver Disease,” concluded that early identification of patients with FLD through broad placement of VCTE™/CAP™ devices offers cost savings to payers.
To learn the results of this independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) that demonstrates how deploying vibration-controlled transient elastography (VCTE™)/controlled attenuation parameter (CAP™) technology for detecting and monitoring FLD can offer payers cost savings, read “FibroScan® Technology Assesses and Monitors Liver Health, Demonstrates Positive Return on Investment.”